Impact of Oseltamivir and Diabetes Development
<b>Background/Objectives</b>: Influenza is a major global health challenge, causing thousands of deaths annually. Antiviral drugs, particularly oseltamivir, a neuraminidase inhibitor, have become essential therapeutic options due to their oral bioavailability and efficacy. Previous studi...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/18/1/128 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <b>Background/Objectives</b>: Influenza is a major global health challenge, causing thousands of deaths annually. Antiviral drugs, particularly oseltamivir, a neuraminidase inhibitor, have become essential therapeutic options due to their oral bioavailability and efficacy. Previous studies suggest a potential association between oseltamivir use and the onset of diabetes mellitus. However, further investigation is needed to establish a definitive link. <b>Methods</b>: This retrospective cohort study utilized data from the Taiwan National Health Insurance Research Database (NHIRD), including 1,631,968 patients (815,984 oseltamivir users) between 1 January 2009 and 28 December 2018. All statistical analyses were performed using SAS 9.4M8 software (SAS Institute Inc., Cary, NC, USA). <b>Results</b>: Cox proportional hazards regression and multivariate analyses revealed a statistically significant association between oseltamivir use and overall diabetes risk (HR = 1.027, <i>p</i> = 0.0186). While no significant association was observed for Type 1 diabetes (HR = 1.021; <i>p</i> = 0.06795), oseltamivir users showed a higher incidence of Type 2 diabetes (HR = 1.024; <i>p</i> < 0.05). Oseltamivir was also linked to increased risks of comorbidities, including dyslipidemia (HR = 1.295, <i>p</i> < 0.0001), chronic liver disease (HR = 1.446, <i>p</i> < 0.0001), hypertension (HR = 1.586, <i>p</i> < 0.0001), and obesity (HR = 2.949, <i>p</i> < 0.0001). <b>Conclusions</b>: Oseltamivir is associated with an increased risk of Type 2 diabetes but not Type 1, and related comorbidities. |
|---|---|
| ISSN: | 1424-8247 |